Market Cap 469.53M
Revenue (ttm) 23.61M
Net Income (ttm) -105.51M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 17.66
Profit Margin -446.89%
Debt to Equity Ratio 0.46
Volume 803,200
Avg Vol 1,238,672
Day's Range N/A - N/A
Shares Out 56.30M
Stochastic %K 12%
Beta 1.08
Analysts Strong Sell
Price Target $22.86

Company Profile

Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 1/2 clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug pro...

Industry: Biotechnology
Sector: Healthcare
Phone: 321 939 3416
Website: zevra.com
Address:
1180 Celebration Boulevard, Suite 103, Celebration, United States
Trend123
Trend123 Jan. 7 at 4:41 AM
$ZVRA So if I understand well, everyone’s making money except us: -HCR( Neil’s 2nd co.) for the 12% loan -GPC aka commave for the loan -Nanthaala and etcetera for Acer aka nothing -Dilutive offering for them to stay in control -Acer management for all the above Also, they kill the momentum each time they can : - the approval - the offering - the 150 M $ - the write off - the lawsuit Pretty sure they expect us to sue them… I would not be surprised if Commave and Neil/HCR planned all that… They had a little something over KMPH in 2019 according to the court . The lawsuit against Commave highlights a reckless management style . This network has a proven track record of managing companies for the benefit of senior debt and private equity, leaving retail shareholders to bear the development risk with a capped reward. Retails remains under constant threat from the institutional network tasked with its stewardship.
0 · Reply
Rookie69
Rookie69 Jan. 6 at 10:14 PM
$ZVRA i had a dream / nightmare the other night that I woke up to an $11.50 buyout news.....now maybe it was more a premonition than dream Would be real nice of Neil and team to issue a 8-K since this does seem to be a "material event"
0 · Reply
kwbdawg
kwbdawg Jan. 6 at 9:14 PM
$ZVRA January effect in full break out here….NOT….a lot of missed opportunities staying in this dog for past month
0 · Reply
DevAd
DevAd Jan. 6 at 7:42 PM
$ZVRA Under competent leadership, this company would be a $25 stock today. Asztarys paired with a capable partner, no “prove nothing” burger launches, and Mayplaifa monetized globally. Instead, we’re left with a level of incompetence that would be amusing if it weren’t costing me real money.
1 · Reply
intowits
intowits Jan. 6 at 7:35 PM
$ZVRA FYI, look at all the advisors involved in the financing. Who checked the licensing agreement? "Latham & Watkins advised in the transaction: -with a deal team led by finance partners Haim Zaltzman & Jennifer Kent, with associates Hyunji Lee, Jessica Lietz, Lindsay Kenney, & Steve Hess. -Advice was also provided on certain corporate matters by partners Nathan Ajiashvili, Christopher Clark, Reza Mojtabaee-Zamani, & Eric Rice; -tax matters by partner Aaron Bernstein, with associate Jacob Nagelberg; -intellectual property matters by partner Chris Hazuka, with associates Robert Yeh & Kristina Funahashi; -healthcare regulatory matters by partners Elizabeth Richards & Betty Pang; with associate Nathan Beaton; -data privacy matters by partner Heather Deixler, with associate Heather Lui; -ERISA matters by partner Nikhil Kumar, with associate Bryce Williamson; & -certain other regulatory matters by partners Nathan Seltzer & Joel Cavanaugh & counsel Andrew Galdes. https://www.lw.com/en/news/2024/04/latham-watkins-advises-zevra-therapeutics-in-us100-million-credit-facility#:~:text=Led%20by%20Perceptive%20Advisors%20and,Cavanaugh%20and%20counsel%20Andrew%20Galdes.
1 · Reply
DevAd
DevAd Jan. 6 at 7:23 PM
$ZVRA Of all competent CEOs we end up witha clown. I'm starting to miss Pascoe!
1 · Reply
DevAd
DevAd Jan. 6 at 7:16 PM
$ZVRA Partnership from hell and a ceo from hell.
1 · Reply
intowits
intowits Jan. 6 at 7:08 PM
$ZVRA when do the ambulance chasers begin to appear? On the financing deal, they did immediately use $60 mil of it. Nothing else. So give Com what they would have earned if it was their's plus a damage vig. Nothing was done with KP1077. No deals, so nothing missed out on. Maybe add a damage vig? Order Z to adhere to the agreement, etc. Does the agreement remain in place afterwards or disposed of? Sell Azstary and KP1077 to Com and be done with them?
0 · Reply
WaynD01
WaynD01 Jan. 6 at 6:37 PM
$ZVRA I was asking how it was possible to go it alone with KP1077 when Travis was saying he could do so as the contract language was saying any KP485 compound is competing product. The answer I was getting that they could do work around by asking an outrageous amount/deal. Looks like the company or lawyers did not care at all. The worst thing is that the new self enriching and greedy CEO Neil collatered the same to his buddy financier for an outrageous fee and interest rate. Any way I assume everything is priced in and the value is with Miplyffa and it is doing great.
1 · Reply
Biotechnicity
Biotechnicity Jan. 6 at 6:33 PM
$ZVRA I apologize for suggesting that damages would be paired to reality. Can someone please tell me how Neil could swoop in; set this up for sale and then be found accountable for a gaffe this large? I honestly don’t understand. The only way I can comprehend it is to go in a direction that it is futile to travel in. Regardless, the judge is entrusted to make both parties whole in this venue. Consequently, damages should be mitigated and reduced accordingly. Awaiting the logical approval of MIPLYFFA in the EU. Not awaiting Hunting. 😉🤣
0 · Reply
Latest News on ZVRA
Zevra Therapeutics, Inc. Announces CFO Transition

Nov 20, 2025, 4:05 PM EST - 6 weeks ago

Zevra Therapeutics, Inc. Announces CFO Transition


Zevra Therapeutics, Inc. (ZVRA) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 8:43 PM EDT - 5 months ago

Zevra Therapeutics, Inc. (ZVRA) Q2 2025 Earnings Call Transcript


Zevra Therapeutics, Inc. (ZVRA) Q1 2025 Earnings Call Transcript

May 13, 2025, 10:45 PM EDT - 8 months ago

Zevra Therapeutics, Inc. (ZVRA) Q1 2025 Earnings Call Transcript


Zevra Therapeutics Files Preliminary Proxy

Mar 31, 2025, 4:12 PM EDT - 10 months ago

Zevra Therapeutics Files Preliminary Proxy


Zevra Therapeutics, Inc. (ZVRA) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 8:16 PM EDT - 10 months ago

Zevra Therapeutics, Inc. (ZVRA) Q4 2024 Earnings Call Transcript


Zevra Reports Full Year 2024 and Fourth Quarter Financial Results

Mar 11, 2025, 4:05 PM EDT - 10 months ago

Zevra Reports Full Year 2024 and Fourth Quarter Financial Results


Zevra to Participate at Upcoming Investor Conferences

Feb 24, 2025, 4:02 PM EST - 11 months ago

Zevra to Participate at Upcoming Investor Conferences


Zevra Therapeutics Announces Organizational Changes

Dec 6, 2024, 5:00 PM EST - 1 year ago

Zevra Therapeutics Announces Organizational Changes


US FDA approves Zevra's genetic disorder treatment

Sep 20, 2024, 10:14 AM EDT - 1 year ago

US FDA approves Zevra's genetic disorder treatment


Trend123
Trend123 Jan. 7 at 4:41 AM
$ZVRA So if I understand well, everyone’s making money except us: -HCR( Neil’s 2nd co.) for the 12% loan -GPC aka commave for the loan -Nanthaala and etcetera for Acer aka nothing -Dilutive offering for them to stay in control -Acer management for all the above Also, they kill the momentum each time they can : - the approval - the offering - the 150 M $ - the write off - the lawsuit Pretty sure they expect us to sue them… I would not be surprised if Commave and Neil/HCR planned all that… They had a little something over KMPH in 2019 according to the court . The lawsuit against Commave highlights a reckless management style . This network has a proven track record of managing companies for the benefit of senior debt and private equity, leaving retail shareholders to bear the development risk with a capped reward. Retails remains under constant threat from the institutional network tasked with its stewardship.
0 · Reply
Rookie69
Rookie69 Jan. 6 at 10:14 PM
$ZVRA i had a dream / nightmare the other night that I woke up to an $11.50 buyout news.....now maybe it was more a premonition than dream Would be real nice of Neil and team to issue a 8-K since this does seem to be a "material event"
0 · Reply
kwbdawg
kwbdawg Jan. 6 at 9:14 PM
$ZVRA January effect in full break out here….NOT….a lot of missed opportunities staying in this dog for past month
0 · Reply
DevAd
DevAd Jan. 6 at 7:42 PM
$ZVRA Under competent leadership, this company would be a $25 stock today. Asztarys paired with a capable partner, no “prove nothing” burger launches, and Mayplaifa monetized globally. Instead, we’re left with a level of incompetence that would be amusing if it weren’t costing me real money.
1 · Reply
intowits
intowits Jan. 6 at 7:35 PM
$ZVRA FYI, look at all the advisors involved in the financing. Who checked the licensing agreement? "Latham & Watkins advised in the transaction: -with a deal team led by finance partners Haim Zaltzman & Jennifer Kent, with associates Hyunji Lee, Jessica Lietz, Lindsay Kenney, & Steve Hess. -Advice was also provided on certain corporate matters by partners Nathan Ajiashvili, Christopher Clark, Reza Mojtabaee-Zamani, & Eric Rice; -tax matters by partner Aaron Bernstein, with associate Jacob Nagelberg; -intellectual property matters by partner Chris Hazuka, with associates Robert Yeh & Kristina Funahashi; -healthcare regulatory matters by partners Elizabeth Richards & Betty Pang; with associate Nathan Beaton; -data privacy matters by partner Heather Deixler, with associate Heather Lui; -ERISA matters by partner Nikhil Kumar, with associate Bryce Williamson; & -certain other regulatory matters by partners Nathan Seltzer & Joel Cavanaugh & counsel Andrew Galdes. https://www.lw.com/en/news/2024/04/latham-watkins-advises-zevra-therapeutics-in-us100-million-credit-facility#:~:text=Led%20by%20Perceptive%20Advisors%20and,Cavanaugh%20and%20counsel%20Andrew%20Galdes.
1 · Reply
DevAd
DevAd Jan. 6 at 7:23 PM
$ZVRA Of all competent CEOs we end up witha clown. I'm starting to miss Pascoe!
1 · Reply
DevAd
DevAd Jan. 6 at 7:16 PM
$ZVRA Partnership from hell and a ceo from hell.
1 · Reply
intowits
intowits Jan. 6 at 7:08 PM
$ZVRA when do the ambulance chasers begin to appear? On the financing deal, they did immediately use $60 mil of it. Nothing else. So give Com what they would have earned if it was their's plus a damage vig. Nothing was done with KP1077. No deals, so nothing missed out on. Maybe add a damage vig? Order Z to adhere to the agreement, etc. Does the agreement remain in place afterwards or disposed of? Sell Azstary and KP1077 to Com and be done with them?
0 · Reply
WaynD01
WaynD01 Jan. 6 at 6:37 PM
$ZVRA I was asking how it was possible to go it alone with KP1077 when Travis was saying he could do so as the contract language was saying any KP485 compound is competing product. The answer I was getting that they could do work around by asking an outrageous amount/deal. Looks like the company or lawyers did not care at all. The worst thing is that the new self enriching and greedy CEO Neil collatered the same to his buddy financier for an outrageous fee and interest rate. Any way I assume everything is priced in and the value is with Miplyffa and it is doing great.
1 · Reply
Biotechnicity
Biotechnicity Jan. 6 at 6:33 PM
$ZVRA I apologize for suggesting that damages would be paired to reality. Can someone please tell me how Neil could swoop in; set this up for sale and then be found accountable for a gaffe this large? I honestly don’t understand. The only way I can comprehend it is to go in a direction that it is futile to travel in. Regardless, the judge is entrusted to make both parties whole in this venue. Consequently, damages should be mitigated and reduced accordingly. Awaiting the logical approval of MIPLYFFA in the EU. Not awaiting Hunting. 😉🤣
0 · Reply
Fire7878
Fire7878 Jan. 6 at 6:21 PM
$ZVRA 9 figures? Really? This law firm should be sued for disinformation.
1 · Reply
ZVRA100
ZVRA100 Jan. 6 at 6:09 PM
$ZVRA i think when we fell from 13 to the price range now of 8, the lawsuit summary was already anticipated and it was baked in. 9 figure remedy will probably just mean 10-40m in total payment over several years + azstarys royalty renegotiation. I think that will likely be removal of milestone payments moving forward, which justifies the “9-figure” remedy. Should have never held Commave’s hands. They failed at launching Azstarys, and now just wants to get every penny that can collect. Overall, I think this is okay for us. Good opportunity to completely cut ties with them.
2 · Reply
intowits
intowits Jan. 6 at 5:36 PM
$ZVRA Sullivan & Cromwell Obtains Summary Judgment Win for Commave Commave obtained a rare early summary judgment win from the Delaware Court, which held that Zevra had breached in 2 material ways a licensing agreement between the 2 companies involving certain patented pharma prods. The ruling addressed an important issue of 1st impression on whether licensing revenue can be collaterally assigned to creditors. In its ruling, Judge Will granted summary judgment to Commave & held that the relevant provisions of the license agreement are unambiguous, & that Zevra’s new drug candidate is a prohibited competing prod. Court also found that Zevra’s collateral assignment of its rights under the license agreement violated Commave’s rights of first negotiation and first refusal. The only issues remaining for trial are the remedies, which in combination, are expected to be of nine-figure value. 😳 Read more: https://www.sullcrom.com/About/News-and-Events/Highlights/2026/January/SC-Obtains-Summary-Judgment-Win-Commave-Therapeutics-Pharmaceutical-Licensing-Dispute
5 · Reply
DevAd
DevAd Jan. 6 at 5:27 PM
$ZVRA What happened to SLS @WaynD01 ? I have no position, but damn what a drop.
3 · Reply
MikeyNJ
MikeyNJ Jan. 6 at 5:04 PM
$ZVRA Unless there is a significant move higher by next Friday, those January $9 calls look to go out worthless. The spread was basically put on for nothing as the investor bought the $9 calls, sold the $14 calls against it, and financed most of the cost selling the December 2026 $5 puts.
1 · Reply
CyberspaceCowboy
CyberspaceCowboy Jan. 6 at 4:50 PM
$ZVRA have to fight so hard for one penny here, really messed up gambling on this stonk.
0 · Reply
CobraConte
CobraConte Jan. 6 at 3:34 PM
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Jan. 6 at 3:13 PM
Enter: $ZVRA Calls Strike Price: $9 Expiry Date: FEB 20 2026 Buy in Price: $1.00 - $1.05 Sell Price: $1.78 Profit : +78% (Turn every $1 into $1.78) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
PencilNeckGeek
PencilNeckGeek Jan. 6 at 3:04 PM
$ZVRA Any chance on $10 in 2026?
2 · Reply
DaveESIX
DaveESIX Jan. 6 at 1:48 PM
$ZVRA question for zevra community - don't have time today to research on my own. I thought there was significance to the end of 2025 as it related to the warrants that have hung over our heads since KMPH days. Was that right or just a wishful memory?
1 · Reply
sirloud13
sirloud13 Jan. 6 at 1:05 PM
0 · Reply
Cube_CH
Cube_CH Jan. 6 at 9:06 AM
0 · Reply